Impact ofCYP2C8*3polymorphism onin vitrometabolism of imatinib to N-desmethyl imatinib

Individualized dosing of tyrosine kinase inhibitors: are we there yet?

(2015) Djoeke de Wit et al.   DRUG DISCOVERY TODAY

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

(2014) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies

(2014) Nicolas Widmer et al.   EUROPEAN JOURNAL OF CANCER

Current and future management of Ph/BCR-ABL positive ALL

(2014) Elena Maino et al.   Expert Review of Anticancer Therapy

Large-scale imatinib dose–concentration–effect study in CML patients under routine care conditions

(2014) Verena Gotta et al.   LEUKEMIA RESEARCH

Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells

(2013) Erik Berglund et al.   ANTI-CANCER DRUGS

Influence ofCYP2C8polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomersin vitro

(2013) Lushan Yu et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes

(2013) Tore B. Stage et al.   Pharmacogenetics and Genomics

PharmGKB summary

(2013) Christina L. Aquilante et al.   Pharmacogenetics and Genomics

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory

(2012) Stéphane Bouchet et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates

(2011) AM Filppula et al.   BRITISH JOURNAL OF PHARMACOLOGY

Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate

(2011) B. M. VandenBrink et al.   DRUG METABOLISM AND DISPOSITION

In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance

(2011) Nitsupa Wattanachai et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection

(2011) Ka Liong Tan et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes

(2010) Noelia Nebot et al.   BRITISH JOURNAL OF PHARMACOLOGY

Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects onin vitroandin vivodrug–drug interactions

(2010) Yiwen Gao et al.   XENOBIOTICA

The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone MetabolismIn Vitro

(2009) Eugen Muschler et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

(2009) Elizabeth B Daily et al.   PHARMACOGENOMICS

In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1

(2008) Bertrand Rochat et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Determinants of Cytochrome P450 2C8 Substrate Binding

(2008) Guillaume A. Schoch et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Impact of genetic polymorphisms inCYP2C8and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids

(2008) Julia Kirchheiner et al.   PHARMACOGENOMICS